Trevi Therapeutics shareholders approve increase in authorized common shares to 400 million

• Trevi Therapeutics held its annual shareholder meeting on June 3, 2026.
• Shareholders ratified Ernst & Young as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Investors adopted an amended and restated 2019 stock incentive plan, lifting the share reserve by 8 million shares.
• Shareholders authorized a charter amendment doubling authorized common shares to 400 million from 200 million; the amendment took effect June 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-257365), on June 04, 2026, and is solely responsible for the information contained therein.